Compare RNW & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | IMCR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.8B |
| IPO Year | 2021 | 2016 |
| Metric | RNW | IMCR |
|---|---|---|
| Price | $6.84 | $33.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 2.9M | 347.6K |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $11.50 | $8.21 |
| P/E Ratio | ★ $14.63 | $149.87 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $4.39 | $27.56 |
| 52 Week High | $8.24 | $40.71 |
| Indicator | RNW | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 38.29 |
| Support Level | $6.78 | $31.90 |
| Resistance Level | $6.85 | $35.73 |
| Average True Range (ATR) | 0.03 | 1.03 |
| MACD | -0.02 | -0.43 |
| Stochastic Oscillator | 60.00 | 2.13 |
ReNew Energy Global PLC is a developer and operator of clean energy projects. Additionally, it provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services that are increasingly integral to addressing climate change. The company has two reportable segments: Generation and sale of renewable power and Manufacturing of power equipment. The majority of its revenue is generated from the Generation and sale of renewable power segment, which reflects the revenue earned from its utility-scale wind energy projects, solar energy projects, and hydro energy projects. The Manufacturing of power equipment segment relates to the manufacturing of solar panels and modules. Geographically, all of its material revenues are generated from India.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.